Does the Gadoxetic Acid-Enhanced Liver MRI Impact on the Treatment of Patients with Colorectal Cancer? Comparison Study with 18F-FDG PETCT

Abstract EN

Objectives.

We evaluated the value of Gadoxetic acid-enhanced liver MRI in the preoperative staging of colorectal cancer and estimated the clinical impact of liver MRI in the management plan of liver metastasis.

Methods.

We identified 108 patients who underwent PET/CT and liver MRI as preoperative evaluation of colorectal cancer, between January 2011 and December 2013.

We evaluated the per nodule sensitivity of PET/CT and liver MRI for liver metastasis.

Management plan changes were estimated for patients with metastatic nodules newly detected on liver MRI, to assess the clinical impact.

Results.

We enrolled 131 metastatic nodules (mean size 1.6 cm) in 41 patients (mean age 65 years).

The per nodule sensitivities of PET/CT and liver MRI were both 100% for nodules measuring 2 cm or larger but were significantly different for nodules measuring less than 2 cm (59.8% and 95.1%, resp., P = 0.0001 ).

At least one more metastatic nodule was detected on MRI in 16 patients.

Among these, 7 patients indicated changes of management plan after performing MRI.

Conclusions.

Gadoxetic acid-enhanced liver MRI detected more metastatic nodules compared with PET/CT, especially for small (<2 cm) nodules.

The newly detected nodules induced management plan change in 43.8% (7/16) of patients.